Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study-Reference-Cited by-同舟云学术

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study

Published:2019-08-26 Issue:8 Volume:14 Page:e0221500
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Kjerpeseth Lars J.^ORCID,Selmer Randi,Ariansen Inger,Karlstad Øystein,Ellekjær Hanne,Skovlund Eva

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference54 articles.

1. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association;AJ Camm;Europace,2012

2. Systematic overview of warfarin and its drug and food interactions;AM Holbrook;Arch Intern Med,2005

3. Dabigatran versus warfarin in patients with atrial fibrillation;SJ Connolly;N Engl J Med,2009

4. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation;MR Patel;N Engl J Med,2011

5. Apixaban versus warfarin in patients with atrial fibrillation;CB Granger;N Engl J Med,2011

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Oral Anticoagulation with Vitamin K Antagonists in Patients Living in a Low-Income Country of West Africa;World Journal of Cardiovascular Diseases;2024

2. The State of Use and Utility of Negative Controls in Pharmacoepidemiologic Studies;American Journal of Epidemiology;2023-10-17

3. Real‐world evidence that among atrial fibrillation patients warfarin is associated with reduced nonelective admissions compared with those on DOACs;Clinical Cardiology;2023-09-08

4. Safety and efficacy of direct oral anticoagulants (DOACs) in very elderly patients (≥85 years old) with non-valvular atrial fibrillation;Minerva Medica;2023-04

5. Comparing the Efficacy and Safety of Apixaban Versus Warfarin in Morbidly Obese Patients;Cureus;2022-10-14